The DOI matches its Crossref record; 48 of the 51 references it cites were found in a registry or an index.
Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas
Open accessAbstract
To predict the prognosis of neuroblastoma patients and choose a better therapeutic protocol, we developed a cDNA microarray carrying 5340 genes obtained from primary neuroblastomas and examined 136 tumor samples. We made a probabilistic output statistical classifier that provided a high accuracy in prognosis prediction (89% at 5 years) and a highly reliable method to validate it. Kaplan-Meier analysis indicated that the patients in an intermediate group defined by existing markers are divided by microarray into two further groups with 5 year survivals for 36% and 89% of patients (p < 10(-4)), i.e., with unfavorably and favorably predicted neuroblastomas, respectively. According to these results, we developed a gene subset chip for a clinical tool, for which our classifier exhibited 88% prediction accuracy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, a number of microarray-based gene expression models have been proposed to predict neuroblastoma patient outcome [16, 17].”
From Comparison of RNA-seq and microarray-based models for clinical endpoint prediction (2015) · cites this paper as [17]
In the citing paper
“The models significantly discriminated patients with favorable and unfavorable outcome in the entire cohort and in the class labeled cohort (Additional file 1: Figure S9a-d, Table S3 and S4), which is consistent with previous observations made by us and others [16–18, 20].”
From Comparison of RNA-seq and microarray-based models for clinical endpoint prediction (2015) · cites this paper as [17]
In the citing paper
“Both gene expression-based models derived from RNA-seq and microarray analyses were capable of predicting patient outcome in the entire neuroblastoma cohort accurately, thereby validating results from previous studies and underscoring their potential clinical utility for risk estimation in neuroblastoma [16–18, 20].”
From Comparison of RNA-seq and microarray-based models for clinical endpoint prediction (2015) · cites this paper as [17]
Citations
Cites
Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1006/abio.1987.9999 · Cited by 65,515
Robust Locally Weighted Regression and Smoothing Scatterplots
Cleveland, W. S. (1979) · Journal of the American Statistical Association · doi:10.1080/01621459.1979.10481038 · Cited by 11,594
Golub, T. R., Slonim, D. K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov, J. P., Coller, H., Loh, M. L., Downing, J. R., Caligiuri, M. A., et al. (1999) · Science · doi:10.1126/science.286.5439.531 · Cited by 11,516
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
Gene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536
Brodeur, G. M., Pritchard, J., Berthold, F., Carlsen, N., Castel, V., Castelberry, R. P., Bernardi, B. D., Evans, A. E., Favrot, M., & Hedborg, F. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1466 · Cited by 2,285
Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage
Brodeur, G. M., Seeger, R. C., Schwab, M., VARMUS, H. E., & Bishop, J. M. (1984) · Science · doi:10.1126/science.6719137 · Cited by 2,261
Gene-expression profiles predict survival of patients with lung adenocarcinoma
Beer, D. G., Kardia, S. L. R., Huang, C.-C., Giordano, T. J., Levin, A. M., Misek, D. E., Lin, L., Chen, G., Gharib, T. G., Thomas, D. G., et al. (2002) · Nature Medicine · doi:10.1038/nm733 · Cited by 2,025
Schwab, M., Alitalo, K. K., Klempnauer, K.-H., VARMUS, H. E., Bishop, J. M., Gilbert, F., Brodeur, G. M., Goldstein, M. N., & Trent, J. M. (1983) · Nature · doi:10.1038/305245a0 · Cited by 1,405
Shimada, H., Chatten, J., Newton, W. A., Sachs, N., Hamoudi, A. B., Chiba, T., Marsden, H. B., & Misugi, K. (1984) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/73.2.405 · Cited by 858
Cited by
Sorted by citations
Recent Advances in Neuroblastoma
Maris, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0804577 · Cited by 2,025
Applications of Machine Learning in Cancer Prediction and Prognosis
Cruz, J. A., & Wishart, D. S. (2006) · Cancer Informatics · doi:10.1177/117693510600200030 · Cited by 1,371
Applications of machine learning in cancer prediction and prognosis.
Cruz, J. A., & Wishart, D. S. (2007) · PubMed Central · Cited by 879
Ambros, P. F., Ambros, I. M., Brodeur, G. M., Haber, M., Khan, J. I., Nakagawara, A., Schleiermacher, G., Speleman, F., Spitz, R. E., London, W. B., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605014 · Cited by 403
Self-citationComparison of RNA-seq and microarray-based models for clinical endpoint prediction
Zhang, W., Yu, Y., Hertwig, F., Thierry-Mieg, J., Zhang, W., Thierry-Mieg, D., Wang, J., Furlanello, C., Devanarayan, V., Cheng, J., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0694-1 · Cited by 393
Technological advancements in cancer diagnostics: Improvements and limitations
Pulumati, A., Pulumati, A., Dwarakanath, B. S. R., Verma, A., & Papineni, R. V. L. (2023) · Cancer Reports · doi:10.1002/cnr2.1764 · Cited by 345
Oberthuer, A., Berthold, F., Warnat, P., Hero, B., Kahlert, Y., Spitz, R., Ernestus, K., König, R., Haas, S., Eils, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1879 · Cited by 291
The molecular pathology of cancer
Harris, T., & McCormick, F. P. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.41 · Cited by 286
Westermann, F., Muth, D., Benner, A., Bauer, T., Henrich, K., Oberthuer, A., Brors, B., Beißbarth, T., Vandesompele, J., Pattyn, F., et al. (2008) · Genome biology · doi:10.1186/gb-2008-9-10-r150 · Cited by 263
Asgharzadeh, S., Pique-Regi, R., Sposto, R., Wang, H., Yang, Y., Shimada, H., Matthay, K., Buckley, J., Ortega, A., & Seeger, R. C. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj330 · Cited by 237
Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification
Valentijn, L. J., Köster, J., Haneveld, F., Ait‐Aissa, R., Sluis, P. V., Broekmans, M. E. C., Molenaar, J. J., van Nes, J., & Versteeg, R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208215109 · Cited by 228
Myc proteins as therapeutic targets
Gustafson, W. C., & Weiss, W. A. (2010) · Oncogene · doi:10.1038/onc.2009.512 · Cited by 204
Vermeulen, J., De Preter, K., Naranjo, A., Vercruysse, L., Van Roy, N., Hellemans, J., Swerts, K., Bravo, S., Scaruffi, P., Tonini, G. P., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70154-8 · Cited by 192
Distinct Genetic Signatures among Pilocytic Astrocytomas Relate to Their Brain Region Origin
Sharma, M. K., Mansur, D. B., Reifenberger, G., Perry, A., Leonard, J. R., Aldape, K., Albin, M. G., Emnett, R. J., Loeser, S., Watson, M. A., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-0973 · Cited by 175
Fredlund, E., Ringnér, M., Maris, J. M., & Påhlman, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804455105 · Cited by 169
Molecular Concepts Analysis Links Tumors, Pathways, Mechanisms, and Drugs
Rhodes, D. R., Sundaram, S. K., Tomlins, S. A., Mahavisno, V., Kasper, N. M., Varambally, R., Barrette, T. R., Ghosh, D., Varambally, S., & Chinnaiyan, A. M. (2007) · Neoplasia · doi:10.1593/neo.07292 · Cited by 139
Prognostic Impact of Gene Expression–Based Classification for Neuroblastoma
Oberthuer, A., Hero, B., Berthold, F., Juraeva, D., Faldum, A., Kahlert, Y., Asgharzadeh, S., Seeger, R., Scaruffi, P., Tonini, G. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.3367 · Cited by 135
p53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma
Chen, L., Iraci, N., Gherardi, S., Gamble, L. D., Wood, K. M., Perini, G., Lunec, J., & Tweddle, D. A. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2598 · Cited by 132
Nakagawara (2009) · International Journal of Oncology · doi:10.3892/ijo_00000219 · Cited by 118
Schramm, A. R., Schulte, J. H., Klein‐Hitpaß, L., Havers, W., Sieverts, H., Berwanger, B., Christiansen, H., Warnat, P., Brors, B., Eils, J., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208936 · Cited by 117
Suenaga, Y., Islam, S. M. R., Alagu, J., Kaneko, Y., Kato, M., Tanaka, Y., Kawana, H., Hossain, S., Matsumoto, D., Yamamoto, M., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1003996 · Cited by 112
Self-citationYarmishyn, A. A., Batagov, A. O., Tan, J. Z., Sundaram, G. M., Sampath, P., Kuznetsov, V. A., & Kurochkin, I. V. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-s9-s7 · Cited by 102
Oberthuer, A., Juraeva, D., Hero, B., Volland, R., Sterz, C., Schmidt, R., Faldum, A., Kahlert, Y., Engesser, A., Asgharzadeh, S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0817 · Cited by 105
Self-citationMolecular pathogenesis of peripheral neuroblastic tumors
Janoueix‐Lerosey, I., Schleiermacher, G., & Delattre, O. (2010) · Oncogene · doi:10.1038/onc.2009.518 · Cited by 101
Fardin, P., Barla, A., Mosci, S., Rosasco, L., Verri, A., Versteeg, R., Caron, H. N., Molenaar, J. J., Øra, I., Eva, A., et al. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-185 · Cited by 102
Preter, K. D., Vermeulen, J., Brors, B., Delattre, O., Eggert, A., Fischer, M., Janoueix‐Lerosey, I., Lavarino, C. E., Maris, J. M., Mora, J., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2607 · Cited by 98
Self-citationAccurate prediction of neuroblastoma outcome based on miRNA expression profiles
Schulte, J. H., Schowe, B., Mestdagh, P., Kaderali, L., Kalaghatgi, P., Schlierf, S., Vermeulen, J., Brockmeyer, B., Pajtler, K. W., Thor, T., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25436 · Cited by 97
Preter, K. D., Mestdagh, P., Vermeulen, J., Zeka, F., Naranjo, A. H., Bray, I. M., Castel, V., Chen, C., Drożyńska, E., Eggert, A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0610 · Cited by 92
Ochiai, H., Takenobu, H., Nakagawa, A., Yamaguchi, Y., Kimura, M., Ohira, M., Okimoto, Y., Fujimura, Y., Koseki, H., Kohno, Y., et al. (2010) · Oncogene · doi:10.1038/onc.2010.22 · Cited by 85
Self-citationTomioka, N., Oba, S., Ohira, M., Misra, A., Fridlyand, J., Ishii, S., Nakamura, Y., Isogai, E., Hirata, T., Yoshida, Y., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210661 · Cited by 80
Self-citationEZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications
Li, Z., Takenobu, H., Setyawati, A. N., Akita, N., Haruta, M., Satoh, S., Shinno, Y., Chikaraishi, K., Mukae, K., Akter, J., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0133-3 · Cited by 79
Self-citationStallings, R. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787315837 · Cited by 74
HOXC9 Links Cell-Cycle Exit and Neuronal Differentiation and Is a Prognostic Marker in Neuroblastoma
Mao, L., Ding, J., Zha, Y., Yang, L., McCarthy, B. A., King, W., Cui, H., & Ding, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0051 · Cited by 72
A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma
García, I., Mayol, G., Ríos, J., Doménech, G., Cheung, N. V., Oberthuer, A., Fischer, M., Maris, J. M., Brodeur, G. M., Hero, B., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2483 · Cited by 63
Advances in the understanding of constitutional and somatic genomic alterations in neuroblastoma
Deyell, R. J., & Attiyeh, E. F. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.03.001 · Cited by 62
The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis
Domingo-Fernandéz, R., Watters, K. M., Piskareva, O., Stallings, R. L., & Bray, I. M. (2012) · Pediatric Surgery International · doi:10.1007/s00383-012-3239-7 · Cited by 61
An integrated cross-platform prognosis study on neuroblastoma patients
Chen, Q., Song, Y., Wei, J. S., Bilke, S., Asgharzadeh, S., Seeger, R. C., & Khan, J. I. (2008) · Genomics · doi:10.1016/j.ygeno.2008.05.014 · Cited by 57
Coco, S., Theißen, J., Scaruffi, P., Stigliani, S., Moretti, S., Oberthuer, A., Valdora, F., Fischer, M., Gallo, F., Hero, B., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27432 · Cited by 58
Fischer, M., Oberthuer, A., Brors, B., Kahlert, Y., Skowron, M., Voth, H., Warnat, P., Ernestus, K., Hero, B., & Berthold, F. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0985 · Cited by 57
The roles of moonlight ribosomal proteins in the development of human cancers
Molavi, G., Samadi, N., & Hosseingholi, E. Z. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27722 · Cited by 56
Plasma midkine level is a prognostic factor for human neuroblastoma
Ikematsu, S., Nakagawara, A., Nakamura, Y., Ohira, M., Shinjo, M., Kishida, S., & Kadomatsu, K. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00957.x · Cited by 55
Self-citationFunctional interplay between MYCN , NCYM , and OCT 4 promotes aggressiveness of human neuroblastomas
Kaneko, Y., Suenaga, Y., Islam, S. M. R., Matsumoto, D., Nakamura, Y., Ohira, M., Yokoi, S., & Nakagawara, A. (2015) · Cancer Science · doi:10.1111/cas.12677 · Cited by 52
Self-citationHigh Genomic Instability Predicts Survival in Metastatic High-Risk Neuroblastoma
Stigliani, S., Coco, S., Moretti, S., Oberthuer, A., Fischer, M., Theißen, J., Gallox, F., Garaventa, A., Berthold, F., Bonassi, S., et al. (2012) · Neoplasia · doi:10.1593/neo.121114 · Cited by 49
High Skp2 Expression Characterizes High-Risk Neuroblastomas Independent of MYCN Status
Westermann, F., Henrich, K., Wei, J. S., Lutz, W., Fischer, M., König, R., Wiedemeyer, R., Ehemann, V., Brors, B., Ernestus, K., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2818 · Cited by 50
Phosphoproteomics for the discovery of kinases as cancer biomarkers and drug targets
Yu, L., Issaq, H. J., & Veenstra, T. D. (2007) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.200700102 · Cited by 47
Nowacki, S., Skowron, M., Oberthuer, A., Fagin, A., Voth, H., Brors, B., Westermann, F., Eggert, A., Hero, B., Berthold, F., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210996 · Cited by 47
ppGalNAc-T13: A New Molecular Marker of Bone Marrow Involvement in Neuroblastoma
Berois, N., Blanc, É., Ripoche, H., Mergui, X., Trajtenberg, F., Cantais, S., Barrois, M., Dessen, P., Kågedal, B., Bénard, J., et al. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2006.067975 · Cited by 46
Roy, N. V., Preter, K. D., Hoebeeck, J., Maerken, T. V., Pattyn, F., Mestdagh, P., Vermeulen, J., Vandesompele, J., & Speleman, F. (2009) · Genome Medicine · doi:10.1186/gm74 · Cited by 46
Kobayashi, K., Era, T., Takebe, A., Jakt, L. M., & Nishikawa, S.-I. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0756 · Cited by 43
Chen, Q., Song, Y., Yu, L., Wei, J. S., Chung, J., Hewitt, S. M., Veenstra, T. D., & Khan, J. I. (2009) · Journal of Proteome Research · doi:10.1021/pr900701v · Cited by 42
GATA factors in human neuroblastoma: distinctive expression patterns in clinical subtypes
Hoene, V., Fischer, M., Ivanova, A., Wallach, T. E., Berthold, F., & Dame, C. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605276 · Cited by 43
Preter, K. D., Brouwer, S. D., Maerken, T. V., Pattyn, F., Schramm, A. R., Eggert, A., Vandesompele, J., & Speleman, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2699 · Cited by 42
Ikram, F., Ackermann, S., Kahlert, Y., Volland, R., Roels, F., Engesser, A., Hertwig, F., Kocak, H., Hero, B., Dreidax, D., et al. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.020 · Cited by 41
Artificial neural network classifier predicts neuroblastoma patients’ outcome
Cangelosi, D., Pelassa, S., Morini, M., Conte, M., Bosco, M. C., Eva, A., Sementa, A. R., & Varesio, L. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-1194-3 · Cited by 42
The Potential Functional Roles of NME1 Histidine Kinase Activity in Neuroblastoma Pathogenesis
Adam, K., Lesperance, J., Hunter, T. R., & Zage, P. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093319 · Cited by 40
Michels, E., Hoebeeck, J., Preter, K. D., Schramm, A. R., Brichard, B., Paepe, A. D., Eggert, A., Laureys, G., Vandesompele, J., & Speleman, F. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-173 · Cited by 38
Theißen, J., Oberthuer, A., Hombach, A., Volland, R., Hertwig, F., Fischer, M., Spitz, R., Zapatka, M., Brors, B., Ortmann, M., et al. (2014) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22174 · Cited by 40
Büchner, A., Castro, M., Hennig, A., Popp, T., Assmann, G., Stief, C. G., & Zimmermann, W. (2010) · Urology · doi:10.1016/j.urology.2010.03.042 · Cited by 41
Shum, C. K. Y., Lau, S.-T., Tsoi, L.-S., Chan, L., Yam, J. W. P., Ohira, M., Nakagawara, A., Tam, P., & Ngan, E. (2012) · Oncogene · doi:10.1038/onc.2012.437 · Cited by 39
Self-citationWu, P., Liao, Y.-F., Juan, H., Huang, H., Wang, B., Lu, Y. C., Yu, I., Shih, Y., Jeng, Y., Hsu, W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088795 · Cited by 36
Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients
Cangelosi, D., Blengio, F., Versteeg, R., Eggert, A., Garaventa, A., Gambini, C., Conte, M., Eva, A., Muselli, M., & Varesio, L. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-s7-s12 · Cited by 34
A 6-gene signature identifies four molecular subgroups of neuroblastoma
Abel, F., Dalevi, D., Nethander, M., Jörnsten, R. J., Preter, K. D., Vermeulen, J., Stallings, R., Kogner, P., Maris, J. M., & Nilsson, S. (2011) · Cancer Cell International · doi:10.1186/1475-2867-11-9 · Cited by 35
The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma
Liguori, L., Andolfo, I., Antonellis, P. D., Aglio, V., Dato, V. D., Marino, N., Orlotti, N. I., Martino, D. D., Capasso, M., Petrosino, G., et al. (2012) · Cell Cycle · doi:10.4161/cc.11.3.19063 · Cited by 32
Warnat, P., Oberthuer, A., Fischer, M., Westermann, F., Eils, R., & Brors, B. (2007) · BMC Cancer · doi:10.1186/1471-2407-7-89 · Cited by 32
Cangelosi, D., Muselli, M., Parodi, S., Blengio, F., Becherini, P., Versteeg, R., Conte, M., & Varesio, L. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-s5-s4 · Cited by 32
Global genomic and RNA profiles for novel risk stratification of neuroblastoma
Ohira, M., & Nakagawara, A. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01681.x · Cited by 31
Self-citationFischer, M., Bauer, T., Oberthür, A., Hero, B., Theißen, J., Ehrich, M., Spitz, R. E., Eils, R., Westermann, F., Brors, B., et al. (2009) · Oncogene · doi:10.1038/onc.2009.390 · Cited by 32
New aspects of neuroblastoma treatment: ASPHO 2011 symposium review
Zage, P. E., Louis, C. U., & Cohn, S. L. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24116 · Cited by 31
Schramm, A. R., Schowe, B., Fielitz, K., Heilmann, M., Martin, M., Marschall, T., Köster, J., Vandesompele, J., Vermeulen, J., Preter, K. D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.391 · Cited by 32
Yagyu, S., Iehara, T., Gotoh, T., Miyachi, M., Katsumi, Y., Kikuchi, K., Tsuchiya, K., Osone, S., Kuroda, H., Sugimoto, T., et al. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.05.032 · Cited by 30
Thorell, K., Bergman, A., Carén, H., Nilsson, S., Kogner, P., Martinsson, T., & Abel, F. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-53 · Cited by 30
Cimmino, F., Spano, D., Capasso, M., Zambrano, N., Russo, R., Zollo, M., & Iolascon, A. (2007) · Journal of Proteome Research · doi:10.1021/pr060701g · Cited by 29
RUNX3 interacts with MYCN and facilitates protein degradation in neuroblastoma
Yu, F., Gao, W., Yokochi, T., Suenaga, Y., Ando, K., Ohira, M., Nakamura, Y., & Nakagawara, A. (2013) · Oncogene · doi:10.1038/onc.2013.221 · Cited by 28
Self-citationYagyu, S., Iehara, T., Tanaka, S., Gotoh, T., Misawa-Furihata, A., Sugimoto, T., London, W. B., Hogarty, M. D., Teramukai, S., Nakagawara, A., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0161039 · Cited by 28
Self-citationTranslating Expression Profiling into a Clinically Feasible Test to Predict Neuroblastoma Outcome
Schramm, A. R., Vandesompele, J., Schulte, J. H., Dreesmann, S., Kaderali, L., Brors, B., Eils, R., Speleman, F., & Eggert, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2032 · Cited by 27
Neuroblastoma genetics and phenotype: A tale of heterogeneity
Speleman, F., Preter, K. D., & Vandesompele, J. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.07.003 · Cited by 27
Oberthuer, A., Kaderali, L., Kahlert, Y., Hero, B., Westermann, F., Berthold, F., Brors, B., Eils, R., & Fischer, M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4377 · Cited by 27
Temozolomide suppresses MYC via activation of TAp63 to inhibit progression of human glioblastoma
Yamaki, T., Suenaga, Y., Iuchi, T., Alagu, J., Takatori, A., Itami, M., Araki, A., Ohira, M., Inoue, M., Kageyama, H., et al. (2013) · Scientific Reports · doi:10.1038/srep01160 · Cited by 25
Self-citationAbel, A. (2009) · International Journal of Oncology · doi:10.3892/ijo_00000196 · Cited by 25
Translational microarray systems for outcome prediction of hepatocellular carcinoma
Iizuka, N., Hamamoto, Y., Tsunedomi, R., & Oka, M. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00751.x · Cited by 25
Rosswog, C., Schmidt, R., Oberthuer, A., Juraeva, D., Brors, B., Engesser, A., Kahlert, Y., Volland, R., Bartenhagen, C., Simon, T., et al. (2017) · Neoplasia · doi:10.1016/j.neo.2017.09.006 · Cited by 24
Yukinawa, N., Oba, S., Kato, K., & Ishii, S. (2008) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2007.70239 · Cited by 24
Self-citationBanerjee, D., Bagchi, S., Liu, Z., Chou, H.-C., Xu, M., Sun, M., Aloisi, S., Vaksman, Z., Diskin, S. J., Zimmerman, M. W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47166-y · Cited by 27
A review of DNA microarray analysis of human neuroblastomas
Ohira, M., Oba, S., Nakamura, Y., Hirata, T., Ishii, S., & Nakagawara, A. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.01.054 · Cited by 22
Self-citationMolecular Characterization and Classification of Neuroblastoma
Oberthuer, A., Theißen, J., Westermann, F., Hero, B., & Fischer, M. (2009) · Future Oncology · doi:10.2217/fon.09.41 · Cited by 21
Corrias, M. V., Parodi, S., Haupt, R., Lacitignola, L., Negri, F., Sementa, A. R., Dau, D., Scuderi, F., Carlini, B., Bianchi, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604179 · Cited by 21
Apoptotic Cell Death in Neuroblastoma
Li, Y., & Nakagawara, A. (2013) · Cells · doi:10.3390/cells2020432 · Cited by 19
Self-citationIdentification of DEIN, a Novel Gene with High Expression Levels in Stage IVS Neuroblastoma
Voth, H., Oberthuer, A., Simon, T., Kahlert, Y., Berthold, F., & Fischer, M. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0258 · Cited by 21
Romano, N., Veronese, M., Manfrini, N., Zolla, L., & Ceci, M. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.09.020 · Cited by 21
Oberthuer, A., Warnat, P., Kahlert, Y., Westermann, F., Spitz, R., Brors, B., Hero, B., Eils, R., Schwab, M., Berthold, F., et al. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.10.016 · Cited by 20
Integrative analysis of neuroblastoma and pheochromocytoma genomics data
Szabó, P. M., Pintér, M., Szabó, D. R., Zsippai, A., Patócs, A., Falus, A., Rácz, K., & Igaz, P. (2012) · BMC Medical Genomics · doi:10.1186/1755-8794-5-48 · Cited by 19
Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome
Cornero, A., Acquaviva, M., Fardin, P., Versteeg, R., Schramm, A. R., Eva, A., Bosco, M. C., Blengio, F., Barzaghi, S., & Varesio, L. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-s4-s13 · Cited by 19
Maggio, V., Chierici, M., Jurman, G., & Furlanello, C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0208924 · Cited by 20
Whole Chromosome Alterations Predict Survival in High-Risk Neuroblastoma without MYCN Amplification
Bilke, S., Chen, Q., Wei, J. S., & Khan, J. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4461 · Cited by 19
Rogers, D. A., & Schor, N. F. (2013) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.12.027 · Cited by 18
Sung, P., Boulos, N., Tilby, M. J., Andrews, W. D., Newbold, R. F., Tweddle, D. A., & Lunec, J. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.08.015 · Cited by 18
Hallett, R. M., Seong, A. B. K., Kaplan, D. R., & Irwin, M. S. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.07.012 · Cited by 14
Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma
Gustafson, W. C., & Matthay, K. K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.103 · Cited by 14
Predicting neuroblastoma using developmental signals and a logic-based model
Kasemeier‐Kulesa, J. C., Schnell, S. D., Woolley, T. E., Spengler, J. A., Morrison, J. A., McKinney, M. C., Pushel, I., Wolfe, L. A., & Kulesa, P. M. (2018) · Biophysical Chemistry · doi:10.1016/j.bpc.2018.04.004 · Cited by 14
Nakagawara, A., Matsumoto, M., Takano, K., Ohira, M., Nakamura, Y., Ozaki, T., Niizuma, H., & Arai, H. (2008) · Oncology Reports · doi:10.3892/or.19.6.1381 · Cited by 14
Self-citation
Metadata
- Authors
- Ohira, M., Oba, S., Nakamura, Y., Isogai, E., Kaneko, S., Nakagawa, A., Hirata, T., Kubo, H., Goto, T., Yamada, S., Yoshida, Y., Fuchioka, M., Ishii, S., & Nakagawara, A.
- Affiliations
- Chiba Cancer Center (JP)
- Nara Institute of Science and Technology (JP)
- University of Tsukuba (JP)
- Aichi Medical University (JP)
- Hisamitsu Pharmaceutical (Japan) (JP)
- NGK Insulators (Japan) (JP)
- SRL (Japan) (JP)
- Corresponding author
- Nakagawara, Akira
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2005-04
- Volume
- 7
- Issue
- 4
- Pages
- 337-350
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2110417418
- Cited by
- 155
- References
- 51
- Citations by year
- 2025: 2 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 3 · 2020: 2 · 2018: 5 · 2017: 1 · 2016: 5 · 2015: 5 · 2014: 8 · 2013: 10 · 2012: 16
- FWCI
- 8.85
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Health, Labour and Welfare
- Ministry of Education, Culture, Sports, Science and Technology
- Topics
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- neuroblastoma, intermediate-risk neuroblastoma, outcome prediction, gene expression profiling, probabilistic classifiers, clinical decision support, survival prediction
- MeSH terms
- Algorithms, Artificial Intelligence, Humans, Neoplasm Staging, Neoplasms, Neuroblastoma, Prognosis, Sensitivity and Specificity, Reproducibility of Results, Models, Statistical, Survival Analysis, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
